Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
No difference in outcomes with antibiotics for Child-Pugh A cirrhosis, variceal bleeding
Researchers reported no difference in rates of infection, rebleeding and mortality when antibiotic prophylaxis was given to stable patients with Child-Pugh A cirrhosis and acute variceal bleeding.
Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results.
Log in or Sign up for Free to view tailored content for your specialty!
Risk for alcohol-related hospitalization fourfold higher in offspring of parents with ALD
Children of parents with alcohol-related liver disease had up to a more than fourfold increased risk for alcohol-related hospitalization, despite a low absolute risk for developing alcohol-related liver disease.
Novel liver dialysis device yields ‘rapid clinical effect’ in patients with liver failure
The Dialive device significantly reduced severity of endotoxemia and improved albumin function in patients with acute-on-chronic liver failure and appears safe with careful patient monitoring, according to data in the Journal of Hepatology.
Cumulative incidence rate for serious infection in NAFLD nears 50% over 20 years
Patients with nonalcoholic fatty liver disease had a significantly greater risk for severe infection requiring hospitalization vs. the general population, with an absolute risk difference of more than 17%at 20 years after diagnosis.
Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo?
In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line.
FDA grants fast track designation to Merck’s efinopegdutide for treatment of NASH
The FDA granted fast track designation to efinopegdutide for the treatment of nonalcoholic steatohepatitis, according to a manufacturer’s press release.
FDA approves Bylvay for cholestatic pruritus due to Alagille syndrome
The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.
Healio seeks nominees for Disruptive Innovators Awards in gastroenterology
Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.
Risk for death in patients with cirrhosis more than twice as high in low-income countries
Patients hospitalized with cirrhosis in low- or middle-income countries had significantly higher risk for mortality compared with patients in high-income countries, according to research in Lancet Gastroenterology & Hepatology.
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read